mucopolysaccharidosis iva
Recently Published Documents


TOTAL DOCUMENTS

101
(FIVE YEARS 17)

H-INDEX

23
(FIVE YEARS 3)

2021 ◽  
Author(s):  
Lorena Diaz-Ordoñez ◽  
Estephania Candelo ◽  
Katherine Silva-Cuero ◽  
Wilmar Saldarriaga ◽  
Lenka Murgasova ◽  
...  

UNSTRUCTURED Objective: This scoping review aimed to understand the extent and type of evidence in relation to physiopathology, classification, epidemiology, clinical management, and effect of therapy for hearing loss in patients with mucopolysaccharidosis (MPS) IVA. Introduction: Mild to moderate hearing loss is common in patients with MPS IVA. The hearing loss can be conductive, sensorineural, or mixed. However, in these patients, the mixed form is frequent, attributed to the combination of conductive and neurosensory elements, with a slowly progressive evolution. Conductive hearing loss may be secondary to recurrent upper respiratory tract infections, serous otitis media, and deformity of the ear ossicles due to accumulation of glycosaminoglycans (GAGs). Meanwhile, the sensorineural form is mainly attributed to the accumulation of GAG in the auditory system.. Inclusion criteria: This scoping review include participants of both sexes, without specific age, who are diagnosed with mucopolysaccharidosis IVA and who develop hearing loss as a comorbidity. None exclusion criteria (country, language or document type) will be applicable. Methods: This scoping review includes participants of both sexes, without specific age, who are diagnosed with MPS IVA and develop hearing loss as comorbidity. No exclusion criteria (country, language, or document type) will be applicable. The information sources will include experimental and quasi-experimental, analytical observational, observational, and qualitative studies. Unpublished literature will not be covered. Gray literature will not be covered. Two independent reviewers will participate in the process of screening the literature, paper selection, and data extraction, and this process will be performed blindly. When all manuscripts have been selected by two reviewers, disagreements that arise between the reviewers at each stage of the selection process will be resolved through discussion or with an additional reviewer. Results will be reported with descriptive statistics and diagrammatic or tabular displayed information as explained in the JBI guidelines.


2021 ◽  
Author(s):  
Alessandra Zanetti ◽  
Francesca D'Avanzo ◽  
Moeenaldeen AlSayed ◽  
Ana Carolina Brusius‐Facchin ◽  
Yin‐Hsiu Chien ◽  
...  

Author(s):  
Zeferino Demartini ◽  
Ricardo Munhoz da Rocha Guimaraes ◽  
Adriane A. Cardoso-Demartini

2021 ◽  
Vol 20 (2) ◽  
pp. 222-231
Author(s):  
Seyed Hosseiali Saberi ◽  
Behnam Kamalidehghan ◽  
Shahla Farshidi ◽  
Seyed Masoud Houshmand ◽  
Roshanak Jazayeri ◽  
...  

2021 ◽  
Vol 14 ◽  
pp. 117954762199940
Author(s):  
Eric Goldman ◽  
Angela Vu ◽  
Kelly Dietz ◽  
Stefani N Thomas

Mucopolysaccharidosis IVA (MPS IVA) is a rare autosomal recessive lysosomal storage disorder resulting from N-acetylgalactosamine-6-sulfatase (GALNS) deficiency that occurs in approximately 1 in 76 000 to 1 in 640 000 live births. Given that the diagnosis of MPS IVA relies heavily on the results of initial urine glycosaminoglycan (GAG) screening, cases that present with falsely normal urine GAG concentrations can delay the diagnosis and follow-up care for patients. This case study follows a patient diagnosed with MPS IVA at 9 months of age based on relation to a consanguineous 3-year-old sibling with MPS IVA and the use of direct enzyme activity analysis. Details regarding skeletal presentation and identification of genetic variants are presented along with data on follow-up urinary GAG monitoring during treatment with enzyme replacement therapy and treatment for a growth hormone disorder.


2020 ◽  
Vol 18 ◽  
pp. 50-61
Author(s):  
Kazuki Sawamoto ◽  
Subha Karumuthil-Melethil ◽  
Shaukat Khan ◽  
Molly Stapleton ◽  
Joseph T. Bruder ◽  
...  

Diagnostics ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 264
Author(s):  
Zhigang Wang ◽  
Yunlan Xu ◽  
Enze Jiang ◽  
Jianmin Wang ◽  
Shunji Tomatsu ◽  
...  

Patients with mucopolysaccharidoses IVA (MPS IVA) have a progressive accumulation of the specific glycosaminoglycans (GAGs): chondroitin-6-sulfate (C6S) and keratan sulfate (KS), leading to the degeneration of the cartilage matrix and its connective tissue perturbing the regular microarchitecture of cartilage and successively distorting bone ossification and growth. Impaired cartilage quality and poor bone mineralization lead to serious hip disorders in MPS IVA patients. Although hip dysplasia is seen widely in musculoskeletal abnormality of this disorder, the pathophysiology of the hip bone and cartilage morphology in these patients remains unclear. Until now, no systemic study of the hip joints in MPS IVA has been reported by using the combined images of plain film radiographs (PFR) and Magnetic Resonance Imaging (MRI). This study aimed to assess the bony and cartilaginous features of hip joints and to explore the potentially related factors of femoral head osteonecrosis (FHN) and hip subluxation/dislocation in patients with MPS IVA. Hip joints in MPS IVA patients were retrospectively reviewed, based on the findings of PFR and MRI data from 2014 to 2019. Demographic information was also collected and analyzed with imaging measurements. A total of 19 patients (eight boys and 11 girls) were recruited, and 38 hip joints in these patients were examined. Eleven patients (57.9%) had FHN. FHN patients were statistically compared with those without FHN. Correlations between cartilaginous femoral head coverage (CFHC) and acetabular index (AI), cartilaginous AI (CAI), or neck-shaft angle (NSA) were investigated in patients with hip subluxation or dislocation. The greater cartilaginous coverage of the hips than their osseous inherency was observed. Significant correlation was observed between CFHC and AI (r =−0.351, p = 0.049) or CAI (r =−0.381, p = 0.032). Severe subluxations or dislocations were more likely to be present in those with more dysplastic bony and cartilaginous hips. In conclusion, our study provides the first systemic description of bony and cartilaginous characteristics in the hip morphology of MPS IVA patients. We have demonstrated that plain radiography alone leads to a misunderstanding of hip morphology and that MRI measurements with PFR are an essential tool to evaluate the ‘true’ characterization of hips for MPS IVA patients.


2020 ◽  
Vol 21 (4) ◽  
pp. 1517 ◽  
Author(s):  
Kazuki Sawamoto ◽  
José Álvarez González ◽  
Matthew Piechnik ◽  
Francisco Otero ◽  
Maria Couce ◽  
...  

Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme. The deficiency of this enzyme accumulates the specific glycosaminoglycans (GAG), keratan sulfate, and chondroitin-6-sulfate mainly in bone, cartilage, and its extracellular matrix. GAG accumulation in these lesions leads to unique skeletal dysplasia in MPS IVA patients. Clinical, radiographic, and biochemical tests are needed to complete the diagnosis of MPS IVA since some clinical characteristics in MPS IVA are overlapped with other disorders. Early and accurate diagnosis is vital to optimizing patient management, which provides a better quality of life and prolonged life-time in MPS IVA patients. Currently, enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) are available for patients with MPS IVA. However, ERT and HSCT do not have enough impact on bone and cartilage lesions in patients with MPS IVA. Penetrating the deficient enzyme into an avascular lesion remains an unmet challenge, and several innovative therapies are under development in a preclinical study. In this review article, we comprehensively describe the current diagnosis, treatment, and management for MPS IVA. We also illustrate developing future therapies focused on the improvement of skeletal dysplasia in MPS IVA.


Sign in / Sign up

Export Citation Format

Share Document